YD Bio Limited (NASDAQ:YDES) Short Interest Update

YD Bio Limited (NASDAQ:YDES) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 42,960 shares, an increase of 223.2% from the August 31st total of 13,293 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 619,936 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of YD Bio

A hedge fund recently raised its stake in YD Bio stock. Cypress Capital Management LLC WY raised its stake in YD Bio Limited (NASDAQ:YDES) by 9.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 33,690 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the period. Cypress Capital Management LLC WY’s holdings in YD Bio were worth $76,000 as of its most recent SEC filing.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded YD Bio to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, YD Bio has a consensus rating of “Sell”.

YD Bio Stock Up 20.1%

NASDAQ YDES traded up $0.96 during mid-day trading on Friday, reaching $5.73. 653,908 shares of the stock were exchanged, compared to its average volume of 663,906. YD Bio has a 1-year low of $1.70 and a 1-year high of $22.00. The business’s fifty day simple moving average is $3.32 and its 200 day simple moving average is $4.19.

YD Bio (NASDAQ:YDES) last released its earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $0.42 million during the quarter.

About YD Bio

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.